Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803586475> ?p ?o ?g. }
- W2803586475 endingPage "4224" @default.
- W2803586475 startingPage "4215" @default.
- W2803586475 abstract "Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors for the manipulability and tolerance of transgenes. Poor tumor selectivity, off-target sequestration, and immune inactivation hamper clinical efficacy. We sought to completely redesign Ad5 into a refined, tumor-selective virotherapy targeted to αvβ6 integrin, which is expressed in a range of aggressively transformed epithelial cancers but nondetectable in healthy tissues.Experimental Design: Ad5NULL-A20 harbors mutations in each major capsid protein to preclude uptake via all native pathways. Tumor-tropism via αvβ6 targeting was achieved by genetic insertion of A20 peptide (NAVPNLRGDLQVLAQKVART) within the fiber knob protein. The vector's selectivity in vitro and in vivo was assessed.Results: The tropism-ablating triple mutation completely blocked all native cell entry pathways of Ad5NULL-A20 via coxsackie and adenovirus receptor (CAR), αvβ3/5 integrins, and coagulation factor 10 (FX). Ad5NULL-A20 efficiently and selectively transduced αvβ6+ cell lines and primary clinical ascites-derived EOC ex vivo, including in the presence of preexisting anti-Ad5 immunity. In vivo biodistribution of Ad5NULL-A20 following systemic delivery in non-tumor-bearing mice was significantly reduced in all off-target organs, including a remarkable 107-fold reduced genome accumulation in the liver compared with Ad5. Tumor uptake, transgene expression, and efficacy were confirmed in a peritoneal SKOV3 xenograft model of human EOC, where oncolytic Ad5NULL-A20-treated animals demonstrated significantly improved survival compared with those treated with oncolytic Ad5.Conclusions: Oncolytic Ad5NULL-A20 virotherapies represent an excellent vector for local and systemic targeting of αvβ6-overexpressing cancers and exciting platforms for tumor-selective overexpression of therapeutic anticancer modalities, including immune checkpoint inhibitors. Clin Cancer Res; 24(17); 4215-24. ©2018 AACR." @default.
- W2803586475 created "2018-06-01" @default.
- W2803586475 creator A5002414723 @default.
- W2803586475 creator A5016792406 @default.
- W2803586475 creator A5019412820 @default.
- W2803586475 creator A5022702970 @default.
- W2803586475 creator A5037850560 @default.
- W2803586475 creator A5047370734 @default.
- W2803586475 creator A5048419544 @default.
- W2803586475 creator A5048427923 @default.
- W2803586475 creator A5051824745 @default.
- W2803586475 creator A5052140429 @default.
- W2803586475 creator A5067715117 @default.
- W2803586475 creator A5069275038 @default.
- W2803586475 creator A5070554485 @default.
- W2803586475 creator A5077500117 @default.
- W2803586475 creator A5078258328 @default.
- W2803586475 date "2018-09-01" @default.
- W2803586475 modified "2023-09-25" @default.
- W2803586475 title "Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies" @default.
- W2803586475 cites W1576773659 @default.
- W2803586475 cites W1780224768 @default.
- W2803586475 cites W1967033604 @default.
- W2803586475 cites W1967589959 @default.
- W2803586475 cites W1968487372 @default.
- W2803586475 cites W1977721242 @default.
- W2803586475 cites W1982651102 @default.
- W2803586475 cites W2011912615 @default.
- W2803586475 cites W2012714016 @default.
- W2803586475 cites W2012874922 @default.
- W2803586475 cites W2022939759 @default.
- W2803586475 cites W2029437600 @default.
- W2803586475 cites W2035503835 @default.
- W2803586475 cites W2037745466 @default.
- W2803586475 cites W2037837054 @default.
- W2803586475 cites W2044570850 @default.
- W2803586475 cites W2048142299 @default.
- W2803586475 cites W2051758487 @default.
- W2803586475 cites W2063556105 @default.
- W2803586475 cites W2063643192 @default.
- W2803586475 cites W2066378267 @default.
- W2803586475 cites W2087077422 @default.
- W2803586475 cites W2093134342 @default.
- W2803586475 cites W2099099776 @default.
- W2803586475 cites W2106528753 @default.
- W2803586475 cites W2110592777 @default.
- W2803586475 cites W2124026197 @default.
- W2803586475 cites W2131119538 @default.
- W2803586475 cites W2135716413 @default.
- W2803586475 cites W2137401341 @default.
- W2803586475 cites W2155108485 @default.
- W2803586475 cites W2158580537 @default.
- W2803586475 cites W2158744232 @default.
- W2803586475 cites W2162161923 @default.
- W2803586475 cites W2173158842 @default.
- W2803586475 cites W2177059217 @default.
- W2803586475 cites W2276190994 @default.
- W2803586475 cites W2314704903 @default.
- W2803586475 cites W2319608467 @default.
- W2803586475 cites W2335064101 @default.
- W2803586475 cites W2516230041 @default.
- W2803586475 cites W2616894489 @default.
- W2803586475 cites W2781905683 @default.
- W2803586475 cites W2781931068 @default.
- W2803586475 cites W2787630633 @default.
- W2803586475 cites W4254732828 @default.
- W2803586475 doi "https://doi.org/10.1158/1078-0432.ccr-18-1089" @default.
- W2803586475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29798908" @default.
- W2803586475 hasPublicationYear "2018" @default.
- W2803586475 type Work @default.
- W2803586475 sameAs 2803586475 @default.
- W2803586475 citedByCount "35" @default.
- W2803586475 countsByYear W28035864752018 @default.
- W2803586475 countsByYear W28035864752019 @default.
- W2803586475 countsByYear W28035864752020 @default.
- W2803586475 countsByYear W28035864752021 @default.
- W2803586475 countsByYear W28035864752022 @default.
- W2803586475 countsByYear W28035864752023 @default.
- W2803586475 crossrefType "journal-article" @default.
- W2803586475 hasAuthorship W2803586475A5002414723 @default.
- W2803586475 hasAuthorship W2803586475A5016792406 @default.
- W2803586475 hasAuthorship W2803586475A5019412820 @default.
- W2803586475 hasAuthorship W2803586475A5022702970 @default.
- W2803586475 hasAuthorship W2803586475A5037850560 @default.
- W2803586475 hasAuthorship W2803586475A5047370734 @default.
- W2803586475 hasAuthorship W2803586475A5048419544 @default.
- W2803586475 hasAuthorship W2803586475A5048427923 @default.
- W2803586475 hasAuthorship W2803586475A5051824745 @default.
- W2803586475 hasAuthorship W2803586475A5052140429 @default.
- W2803586475 hasAuthorship W2803586475A5067715117 @default.
- W2803586475 hasAuthorship W2803586475A5069275038 @default.
- W2803586475 hasAuthorship W2803586475A5070554485 @default.
- W2803586475 hasAuthorship W2803586475A5077500117 @default.
- W2803586475 hasAuthorship W2803586475A5078258328 @default.
- W2803586475 hasBestOaLocation W28035864751 @default.
- W2803586475 hasConcept C102230213 @default.
- W2803586475 hasConcept C104317684 @default.
- W2803586475 hasConcept C111599444 @default.